cht101
Relapsed / Refractory Solid Tumor
Tianjin Medical University Cancer Institute and HospitalCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Relapsed / Refractory Solid Tumor cohort.
Same molecule, other indications
cht101 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →